Navigation Links
Palatin Technologies and King Pharmaceuticals Report Data Showing,Improvements in Sexual Relationship and Self-Esteem in Patients,with Erectile Dysfunction Treated with Bremelanotide

CRANBURY, N.J., and BRISTOL, Tenn., May 22, 2007 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. and King Pharmaceuticals, Inc. reported today that data from Study 16 and Study 17 of the Phase 2B clinical trial program evaluating bremelanotide in men with erectile dysfunction (ED) were presented yesterday at the American Urological Association (AUA) Annual Meeting (AUA 2007) held in Anaheim, CA. New positive data presented showed that bremelanotide improved both self-esteem and sexual relationship in men with erectile dysfunction (ED). Other positive top line data from the Phase 2B clinical trial program were reported by the companies in November 2006 and at the 9th European Society for Sexual Medicine (ESSM) Congress in Vienna in December 2006.

In order to better understand the effects that bremelanotide may have on improving quality of life and self-esteem, patients in Study 16 were administered the SEAR (Self-Esteem and Relationship), a validated psychological instrument with two major domains: sexual relationship and confidence. The SEAR data were presented at AUA 2007 by Stanley E. Althof, PhD, Professor of Psychology, Case Western Reserve School of Medicine in a session entitled Improvement in Sexual Relationship, Satisfaction, Confidence and Self-Esteem in Erectile Dysfunction Patients Treated with Bremelanotide.

Dr. Althof commented, "Our analysis has shown that treatment with bremelanotide improved both the Self-Esteem and Sexual Relationship domains of the SEAR in non-diabetic ED patients and this was strongly correlated with improvements in erectile function. These results indicate that bremelanotide improves sexual confidence and has the potential to be an important treatment option for patients with ED."

"An increasing focus and attention on the utility of therapy in restoring quality of life and improvements to interpersonal relationships continues to evolve and will driv
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
2. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
3. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
4. Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference on Antiviral Research Meeting
5. Micell Technologies Presents Data on Novel Drug-Eluting Stents
6. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
7. AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research
8. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:7/23/2008)...nds Some Areas of the Body Have Greater Concentrat... 23 /PRNewswire-USNewswire/ -- Fat removed,from th...n was found to be,an excellent source of stem cell... areas of the body, reports a Brazilian-based stud...), the official medical journal of the,American So...
(Date:7/22/2008)...tralia, July 22 /- Followin... the Board of Progen,Pharmaceuticals Limited (ASX:...scontinued the PI-88 phase 3 study in liver cancer...lop its existing portfolio of compounds and,the co...pounds and,opportunities through Merger & Acquisit...
(Date:7/22/2008)...g to Discuss Development Plan Completed Successful...l/ -- Amarin Corporation,plc (NASDAQ: AMRN ) toda...icials at the U.S. Food and Drug Administration (F...01 for the treatment of,hypertriglyceridemia. Foll... to Phase 3 with AMR101 in hypertriglyceridemia., ...
(Date:7/22/2008)...llan Will Stress the Importance to Patients of Pas...al Pathway, RICHMOND, Va., July 22 /PRNewswire-Fi...per of follow-on biologics and biopharmaceuticals,...f Insmed, will present at a,Congressional briefing...cant need for establishing an approval pathway for...
Breaking Medicine Technology:Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3Kendle Invites You to Attend Its Fourth Quarter and Year End 2007 Earnings Conference Call and Webcast 10496 1Kendle Invites You to Attend Its Fourth Quarter and Year End 2007 Earnings Conference Call and Webcast 10496 2Markets of biodiversity and equity in trade 3A An illusion 3F 2058 1Markets of biodiversity and equity in trade 3A An illusion 3F 2058 2Markets of biodiversity and equity in trade 3A An illusion 3F 2058 3American Journal of Disaster Medicine Accepted for Inclusion into The National Library of Medicines MEDLINE Database and may now be Accessed Through t 10495 1American Journal of Disaster Medicine Accepted for Inclusion into The National Library of Medicines MEDLINE Database and may now be Accessed Through t 10495 2Life 3AWIRE 28TM 29 to Provide Action Healthcare Management with Innovative Mobile Health Management Solution for Patients with Chronic Conditions 10492 1Life 3AWIRE 28TM 29 to Provide Action Healthcare Management with Innovative Mobile Health Management Solution for Patients with Chronic Conditions 10492 2
... /PRNewswire-FirstCall/ -- Iomai,Corporation today...Phase 1 trial of its patch-based needle-free influ...onference call and live,webcast will be held at 8:...ts. , Conference Call Details , To access the live... Eastern Time via phone, please dial 888-396-2356 ...
... 2007 - HepaLife Technologies, Inc.,(OTCBB:HPLF) (...entific presentation of its cell based PBS-1 techn...t the "Options for the,Control of Influenza VI Con... Canada., Entitled "High titer growth of human and...embryo cell line without the need for,exogenous pr...
Other Medicine Technology:Iomai to Announce Results From Phase 1 Influenza Trial and Host,Webcast Tomorrow 2HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 2HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 3HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 4HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 5
(Date:7/25/2008)...ON, July 25 /PRNewswire/ -- The Elekta Family of C... treatment solutions at the 2008,American Associat...g,demonstrating how the joint forces of Elekta, I... therapy planning and delivery solutions that,stre...perience for,patients, as well as enhance clinicia...
(Date:7/25/2008)...ds fluid back-up in esophagus can cause immune sys...ay News) -- The first evidence linking gastroesoph...scovered by Duke University Medical Center researc...ns was first noted in the 1970s, and since then st...rcent of asthma patients also experience GERD symp...
(Date:7/25/2008)... The Retina Group of New York will...ted macular degeneration especially designed for s...e Public Library at 116 Merritts Road, Farmingdale.... Attendance is free and refreshments will be prov...6) 939-6100. , Hicksville...
(Date:7/25/2008)... This donation will be used to fac...ve services for children , ... ( www.ivci.com ), a leading integrator of enterp...tion video conferencing, telepresence, audio visua...announced today that it has donated video conferen...
Breaking Medicine News(10 mins):Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:People With GERD More Likely to Develop Asthma 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2
... (SARS) epidemic in China has lessons to teach hos...ratory diseases// , according to new research appe... Diseases, currently available online. Hospitals ...n Guangzhou province and Hong Kong in 2003. In hos...
...fresh attack on genetically modified maize develop...ay that rats// fed on one version developed liver ...ad commissioned that was published in the journal ...n and Technology showed rats fed for 90 days on Mo...
...fying agent which could make vaccines for the H5N1...r to produce//. The development could help develo...ndemic struggling to access and afford the vaccine...ockpiled by developed countries. Researchers from...
... junk food in school canteens following a report b...DDRC in its report// has shown concern about the i...betes. A survey carried out by DDRC in 38 schools...n is clinically unhealthy or obese and junk food r...
Other Medicine News:Health News:Study Identifies Risk Factors for Spread of Respiratory Infections in Hospitals 2Health News:Brazilian Boost for Bird Flu Vaccines 2Health News:Brazilian Boost for Bird Flu Vaccines 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens
Medicine Products: